Table 2 Multivariate analysis of clinical, pathologic, and MRI findings associated with NAC invasion by underlying breast cancer
Free NAC n = 92 | Malignant NAC invasion n = 33 | β | P | Odds ratio (95% CI) | |
|---|---|---|---|---|---|
TS/cm | n =7 2 | n = 21 | |||
≤ 2cm | 13 (18.1) | 0 (0.0) | 20.51 | 0.99 | Undefined |
> 2 cm | 59 (81.9) | 21 (100.0) | |||
TND/cm | |||||
≤ 2 cm | 25 (27.2) | 21 (63.6) | 1.54 | < 0.001* | 4.69 (2.02–10.92) |
> 2 cm (R) | 67 (72.8) | 12 (36.4) | Reference group | ||
Abnormal nipple enhancement | |||||
Present | 2 (2.2) | 19 (57.6) | 4.12 | < 0.001* | 61.07 (12.81–291.22) |
Absent (R) | 90 (97.8) | 14 (42.4) | Reference group | ||
NM (nipple morphology) | |||||
Normal (R) | 86 (93.5) | 12 (36.4) | Reference group | ||
Abnormal | 6 (6.5) | 21 (63.6) | 3.22 | < 0.001* | 25.08(8.43-74.6) |
Sym NM (symmetry of nipple morphology) | |||||
Symmetric (R) | 89 (96.7) | 12 (36.4) | Reference group | ||
Asymmetric | 3 (3.3) | 21 (63.6) | 3.95 | < 0.001* | 51.92 (13.44–200.58) |
TT (tumor type) | |||||
DCIS(R ) | 3 (3.3) | 6 (18.2) | −1.80 | 0.015* | Reference group |
IDC | 82 (89.1) | 27 (81.8) | - | 0.99 | 0.165 (0.039–0.704) |
Invasive lobular carcinoma | 7 (7.6) | 0 (0.0) | 21.89 | Undefined | |
TNE (tumor nipple enhancement) | |||||
Present | 22 (23.9) | 24 (72.7) | 2.14 | < 0.001* | 8.48 (3.44–20.94) |
Absent (R) | 70 (76.1) | 9 (27.3) | Reference group | ||
PST (peri-areolar skin thickening) | |||||
Present | 0 (0.0) | 22 (66.7) | |||
Absent | 92 (100.0) | 11 (33.3) | 23.32 | 0.999 | Undefined |
PR (Progesterone receptor state) | |||||
Positive | 50 (54.3) | 26 (78.8) | 3.12 (1.23–7.91) | ||
Negative(R ) | 42 (45.7) | 7 (21.2) | 1.14 | 0.016* | Reference group |
HER 2 | |||||
Positive | 51 (55.4) | 31 (93.9) | 2.523 | 0.001* | 12.46 (2.71–55.17) |
Negative or equivocal | 41 (44.6) | 2 (6.1) | Reference group |